8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II Trials
Nicoletta Colombo(University of Milano-Bicocca), Antonio González-Martı́n(Spanish Ovarian Cancer Research Group), Mariusz Bidziński, Antonio Nieto, C. Kurzedei, Juhui J. Jiao, C. Sessa(Vita-Salute San Raffaele University), Jalid Sehouli(Charité - Universitätsmedizin Berlin), Karin Boman, José María Del Campo
Cited by 2
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2013|1.1k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
|International Journal of Gynecological Cancer|2015|757